BipolarCentral
Your One Stop Source For Information On Bipolar Disorder

Loved One With Bipolar Disorder?
Discover how to cope and deal
With your loved one's bipolar.
Click here for FREE information.
 

Do You Have Bipolar Disorder?
Discover how to cope and deal
With your bipolar disorder.
Click here for FREE information.
 

Child With Bipolar Disorder?
Learn How to REALLY Help
And Support Your Child.
Click here for FREE information.
 

Dating Someone With Bipolar?
Secrets Revealed.
Click here for FREE information.
 

Marrying Someone With Bipolar?
Avoid Mistakes.
Click here for FREE information.

Need Money Because of Bipolar Disorder?
Click here for FREE Report
 

Drug Addiction and Bipolar Disorder
Secrets to Beating It
Click here for FREE information.
 

Need Affordable High
Quality Health Insurance?
Click here for FREE information.
 

In Debt Because of Bipolar Disorder?
Get out of debt fast.
Click here for FREE information.
 

Improve Your Emotional Health
Reduce Your Stress Levels
Increase Your Brain Power
Click here for more information.

Bipolar News

December 1, 2005

Note: One or more of the following articles may require a subscription to view the entire article.  We cannot post articles that require a subscription.  We are sorry for the inconvenience.

Man Arrested for Slaying Family Says He Can't Believe He Did
FOX News - USA
... What led to the incident, Henderson said in the interviews with the Herald, was his mental illness, not drugs. "I've been bipolar since I was 13," he said. ...

Confidential records of students accidentally posted online
Eyewitness News - East Providence,RI,USA
... The most recent are from last year. They disclose things including suicide attempts, bipolar disorders and substance abuse problems. ...

Boy sentenced for photographing sex acts with minors
Sheboygan Press - Sheboygan,WI,USA
... Imig has claimed that a mental disease, bipolar disorder, played a part in his actions, but Van Akkeren said that is not a valid defense. ...

Ending mental illness stigma
Baltimore Sun Fri, 02 Dec 2005 0:31 AM PST
With help of NAMI, author Campbell tries to increase awareness in black community Long before she wrote 72 Hour Hold, a searing account of a mother struggling with her child's bipolar disorder, novelist Bebe Moore Campbell fought her own suspicions that a close relative had a mental illness. At many points, she says, she would have felt devastated, but relieved, to discover a drug addiction was

Suspect in shooting didn't realize targets were police
Dallas Morning News Fri, 02 Dec 2005 5:30 AM PST
MANSFIELD - In his first public statements since his arrest, Stephen Lance Heard said he thought he was being robbed when he fired at Fort Worth police Officer Henry "Hank" Nava Jr.

Manatee man says he can't believe he killed his family
Orlando Sentinel Fri, 02 Dec 2005 8:19 AM PST
A 20-year-old man who has confessed to fatally bludgeoning four members of his family on Thanksgiving said he is severely mentally ill and can't explain why he did it.

Mom's lithium use may harm the baby
Reuters via Yahoo! News Thu, 01 Dec 2005 9:33 AM PST
Fetal exposure to high concentrations of the mood-stabilizer lithium may be harmful to the fetus, possibly contributing to low Apgar scores -- a test used to evaluate babies shortly after birth -- and neuromuscular complications, according to a study.

New Drug Application Submitted for Potential New Treatment for Schizophrenia.

PR Newswire; 11/30/2005

TITUSVILLE, N.J., Nov. 30 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, LLC announced that it has submitted a New Drug Application to the United States Food and Drug Administration (FDA) for Paliperidone Extended-Release (ER) Tablets, an investigational extended- release, once daily, oral medication for the treatment of schizophrenia.

Paliperidone ER uses the patented OROS technology, which releases drug into the bloodstream steadily over a 24-hour period. Paliperidone ER will be marketed in the United States by Janssen, L.P., a wholly owned subsidiary of Johnson & Johnson. The trade name for the marketed product has not yet been determined.

The paliperidone ER filing is based on an extensive global clinical development program that involved more than 1,600 patients in 23 countries. Regulatory submissions are expected to follow for paliperidone ER in other countries.

Schizophrenia affects more than 2 million Americans and is characterized by symptoms such as hallucinations, delusions, social withdrawal and a diminished capacity for organized thought.

Janssen, L.P. is based in Titusville, N.J., and focuses exclusively on pioneering solutions for healthy minds and currently markets prescription medications for the treatment of schizophrenia and bipolar mania. For more information about Janssen, L.P. visit http://www.janssen.com/.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99(b) of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2005. Copies of this Form 10-K are available online at http://www.sec.gov/ or on request from Johnson & Johnson. Johnson & Johnson assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.)

CONTACT: Media, Srikant Ramaswami, +1-609-730-2612, sramaswa@gpcus.jnj.com; or Investors, Stan Panasewicz, +1-732-524-2524, both for Johnson & Johnson Pharmaceutical Research & Development, LLC

Web site: http://www.janssen.com/

COPYRIGHT 2005 PR Newswire Association LLC

Back to Index

Terms of Service | Privacy Policy

Copyright 2004-2008, BipolarCentral.com